rs372260609

Variant summary

Our verdict is Likely benign. Variant got -1 ACMG points: 1P and 2B. PM2_SupportingBP4BS3_Supporting

This summary comes from the ClinGen Evidence Repository: The NM_000156.6:c.471T>G variant in GAMT is a missense variant predicted to cause the substitution of a phenylalanine for a leucine at amino acid position 157 (p.Phe157Leu). This variant has been identified in two individuals in the Exome Variant Server database without detailed phenotypic information available (PMID:26003046). The highest population frequency in gnomAD v4.1.0. is 0.00002119 (25/1180010 alleles) in the European (Non-Finnish) population, which is lower than the ClinGen CCDS VCEP’s threshold for PM2_Supporting (<0.0004), meeting this criterion (PM2_Supporting). Expression of the variant in HeLa cells resulted in similar activity versus wild-type GAMT, indicating that this variant does not impact protein function (PMID:26003046) (BS3_Supporting). The computational predictor REVEL gives a score of 0.259 which is below the threshold of 0.29, evidence that does not predict a damaging effect on GAMT function (BP4). There is a ClinVar entry for this variant (Variation ID: 517082). Although there is conflicting evidence, with two benign criteria were met (BP4 and BS3_Supporting) and one pathogenic criterion met (PM2_Supporting), the consensus from the ClinGen CCDS VCEP is that this variant is likely benign for GAMT deficiency, based upon the in silico and functional evidence. GAMT-specific ACMG/AMP codes met, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes VCEP (Specifications Version 2.0.0): PM2_Supporting, BS3_Supporting, BP4 (classification modified to likely benign)(Classification approved by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel on November 14, 2024) LINK:https://erepo.genome.network/evrepo/ui/classification/CA9043635/MONDO:0012999/026

Frequency

Genomes: 𝑓 0.000013 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000016 ( 0 hom. )

Consequence

GAMT
NM_000156.6 missense

Scores

1
4
14

Clinical Significance

Likely benign reviewed by expert panel U:1B:2

Conservation

PhyloP100: 0.855
Variant links:
Genes affected
GAMT (HGNC:4136): (guanidinoacetate N-methyltransferase) The protein encoded by this gene is a methyltransferase that converts guanidoacetate to creatine, using S-adenosylmethionine as the methyl donor. Defects in this gene have been implicated in neurologic syndromes and muscular hypotonia, probably due to creatine deficiency and accumulation of guanidinoacetate in the brain of affected individuals. Two transcript variants encoding different isoforms have been described for this gene. Pseudogenes of this gene are found on chromosomes 2 and 13. [provided by RefSeq, Feb 2012]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_benign. Variant got -1 ACMG points.

PM2
For more information check the summary or visit ClinGen Evidence Repository.
BP4
For more information check the summary or visit ClinGen Evidence Repository.
BS3
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GAMTNM_000156.6 linkc.471T>G p.Phe157Leu missense_variant Exon 5 of 6 ENST00000252288.8 NP_000147.1 Q14353-1V9HWB2
GAMTNM_138924.3 linkc.471T>G p.Phe157Leu missense_variant Exon 5 of 5 NP_620279.1 Q14353-2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GAMTENST00000252288.8 linkc.471T>G p.Phe157Leu missense_variant Exon 5 of 6 1 NM_000156.6 ENSP00000252288.1 Q14353-1

Frequencies

GnomAD3 genomes
AF:
0.0000131
AC:
2
AN:
152180
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000294
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000120
AC:
3
AN:
250792
Hom.:
0
AF XY:
0.00
AC XY:
0
AN XY:
135804
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000265
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000164
AC:
24
AN:
1461138
Hom.:
0
Cov.:
33
AF XY:
0.0000124
AC XY:
9
AN XY:
726860
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000207
Gnomad4 OTH exome
AF:
0.0000166
GnomAD4 genome
AF:
0.0000131
AC:
2
AN:
152180
Hom.:
0
Cov.:
32
AF XY:
0.0000269
AC XY:
2
AN XY:
74348
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000294
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.000125
Hom.:
0
Bravo
AF:
0.00000756
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000233
AC:
2
ExAC
AF:
0.00000824
AC:
1
EpiCase
AF:
0.000109
EpiControl
AF:
0.00

ClinVar

Significance: Likely benign
Submissions summary: Uncertain:1Benign:2
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Cerebral creatine deficiency syndrome Uncertain:1
Aug 31, 2021
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This sequence change replaces phenylalanine with leucine at codon 157 of the GAMT protein (p.Phe157Leu). The phenylalanine residue is moderately conserved and there is a small physicochemical difference between phenylalanine and leucine. This variant is present in population databases (rs372260609, ExAC 0.002%). This variant has not been reported in the literature in individuals affected with GAMT-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. Experimental studies have shown that this missense change does not substantially affect GAMT function (PMID: 26003046). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

not specified Benign:1
Nov 08, 2017
GeneDx
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

Deficiency of guanidinoacetate methyltransferase Benign:1
Nov 14, 2024
ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel, ClinGen
Significance: Likely benign
Review Status: reviewed by expert panel
Collection Method: curation

The NM_000156.6:c.471T>G variant in GAMT is a missense variant predicted to cause the substitution of a phenylalanine for a leucine at amino acid position 157 (p.Phe157Leu). This variant has been identified in two individuals in the Exome Variant Server database without detailed phenotypic information available (PMID: 26003046). The highest population frequency in gnomAD v4.1.0. is 0.00002119 (25/1180010 alleles) in the European (Non-Finnish) population, which is lower than the ClinGen CCDS VCEP’s threshold for PM2_Supporting (<0.0004), meeting this criterion (PM2_Supporting). Expression of the variant in HeLa cells resulted in similar activity versus wild-type GAMT, indicating that this variant does not impact protein function (PMID: 26003046) (BS3_Supporting). The computational predictor REVEL gives a score of 0.259 which is below the threshold of 0.29, evidence that does not predict a damaging effect on GAMT function (BP4). There is a ClinVar entry for this variant (Variation ID: 517082). Although there is conflicting evidence, with two benign criteria met (BP4 and BS3_Supporting) and one pathogenic criterion met (PM2_Supporting), the consensus from the ClinGen CCDS VCEP is that this variant is likely benign for GAMT deficiency, based upon the in silico and functional evidence. GAMT-specific ACMG/AMP codes met, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes VCEP (Specifications Version 2.0.0): PM2_Supporting, BS3_Supporting, BP4 (classification modified to likely benign) (Classification approved by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel on November 14, 2024) -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.76
BayesDel_addAF
Benign
-0.012
T
BayesDel_noAF
Benign
-0.19
CADD
Benign
15
DANN
Benign
0.91
DEOGEN2
Benign
0.38
T;.;.
Eigen
Benign
-0.71
Eigen_PC
Benign
-0.64
FATHMM_MKL
Uncertain
0.86
D
LIST_S2
Benign
0.75
T;T;T
M_CAP
Uncertain
0.15
D
MetaRNN
Benign
0.15
T;T;T
MetaSVM
Benign
-0.61
T
MutationAssessor
Uncertain
2.3
M;.;M
PrimateAI
Uncertain
0.55
T
PROVEAN
Benign
-1.4
N;.;N
REVEL
Benign
0.26
Sift
Benign
0.61
T;.;T
Sift4G
Benign
0.67
T;.;T
Polyphen
0.0
B;.;.
Vest4
0.23
MutPred
0.38
Gain of catalytic residue at F157 (P = 0.0261);.;Gain of catalytic residue at F157 (P = 0.0261);
MVP
0.82
MPC
0.18
ClinPred
0.10
T
GERP RS
0.54
Varity_R
0.14
gMVP
0.58

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs372260609; hg19: chr19-1399014; API